Laurence A Boxer1, Audrey Anna Bolyard, Merideth L Kelley, Tracy M Marrero, Lan Phan, Jordan M Bond, Peter E Newburger, David C Dale. 1. Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, Michigan; the Department of Medicine, Severe Chronic Neutropenia International Registry, and the Department of Medicine, University of Washington, Seattle, Washington; the University of Louisville School of Medicine, Louisville, Kentucky; and the Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.
Abstract
OBJECTIVE: To report outcomes associated with the administration of granulocyte colony-stimulating factor (G-CSF) to women with chronic neutropenia during pregnancy. METHODS: We conducted an observational study of women of childbearing potential with congenital, cyclic, idiopathic, or autoimmune neutropenia enrolled in the Severe Chronic Neutropenia International Registry to determine outcomes of pregnancies, without and with chronic G-CSF therapy, 1999-2014. Treatment decisions were made by the patients' personal physicians. A research nurse conducted telephone interviews of all enrolled U.S. women of childbearing potential using a standard questionnaire. Comparisons used Fisher's exact test analysis and Student's t test. RESULTS: One hundred seven women reported 224 pregnancies, 124 without G-CSF therapy and 100 on chronic G-CSF therapy (median dose 1.0 micrograms/kg per day, range 0.02-8.6 micrograms/kg per day). There were no significant differences in adverse events between the groups considering all pregnancies or individual mothers, for example, spontaneous terminations (all pregnancies: no G-CSF in 27/124, G-CSF in 13/100; P=.11, Fisher's exact test), preterm labors (all pregnancies, no G-CSF in 9/124, G-CSF in 2/100, P=.12). A study with at least 300 per group would be needed to detect a difference in these events with 80% statistical power (α=0.05). Four newborns of mothers with idiopathic or autoimmune neutropenia not on G-CSF (4/101) had life-threatening infections, whereas there were no similar events (0/90) in the treated group, but this difference was also not statistically significant (P=.124). Adverse events in the neonates were similar for the two groups. CONCLUSION: This observational study showed no significant adverse effects of administration of G-CSF to women with severe chronic neutropenia during pregnancy. LEVEL OF EVIDENCE: III.
OBJECTIVE: To report outcomes associated with the administration of granulocyte colony-stimulating factor (G-CSF) to women with chronic neutropenia during pregnancy. METHODS: We conducted an observational study of women of childbearing potential with congenital, cyclic, idiopathic, or autoimmune neutropenia enrolled in the Severe Chronic Neutropenia International Registry to determine outcomes of pregnancies, without and with chronic G-CSF therapy, 1999-2014. Treatment decisions were made by the patients' personal physicians. A research nurse conducted telephone interviews of all enrolled U.S. women of childbearing potential using a standard questionnaire. Comparisons used Fisher's exact test analysis and Student's t test. RESULTS: One hundred seven women reported 224 pregnancies, 124 without G-CSF therapy and 100 on chronic G-CSF therapy (median dose 1.0 micrograms/kg per day, range 0.02-8.6 micrograms/kg per day). There were no significant differences in adverse events between the groups considering all pregnancies or individual mothers, for example, spontaneous terminations (all pregnancies: no G-CSF in 27/124, G-CSF in 13/100; P=.11, Fisher's exact test), preterm labors (all pregnancies, no G-CSF in 9/124, G-CSF in 2/100, P=.12). A study with at least 300 per group would be needed to detect a difference in these events with 80% statistical power (α=0.05). Four newborns of mothers with idiopathic or autoimmune neutropenia not on G-CSF (4/101) had life-threatening infections, whereas there were no similar events (0/90) in the treated group, but this difference was also not statistically significant (P=.124). Adverse events in the neonates were similar for the two groups. CONCLUSION: This observational study showed no significant adverse effects of administration of G-CSF to women with severe chronic neutropenia during pregnancy. LEVEL OF EVIDENCE: III.
Authors: John M Gansner; Maureen M Achebe; Kathryn J Gray; Revital Yefidoff-Freedman; Elena Labovitis; Aric Parnes; Jean M Connors; Nathan T Connell; Marie N Discenza; Robert I Handin; Nancy Berliner; Akiko Shimamura; Elizabeth S Ginsburg; Nicole A Smith Journal: Blood Date: 2017-08-10 Impact factor: 22.113
Authors: Tal Sella; Pedro Exman; Siyang Ren; Taylor S Freret; Katherine E Economy; Wendy Y Chen; Heather A Parsons; Nancy U Lin; Beverly Moy; Nadine M Tung; Ann H Partridge; Nabihah Tayob; Erica L Mayer Journal: Breast Cancer Res Treat Date: 2022-06-17 Impact factor: 4.624
Authors: David C Dale; Audrey Anna Bolyard; Tracy Marrero; Merideth L Kelley; Vahagn Makaryan; Emily Tran; Jamie Leung; Laurence A Boxer; Priya S Kishnani; Stephanie Austin; Corbinian Wanner; Iris A Ferrecchia; Dina Khalaf; Dawn Maze; Joanne Kurtzberg; Cornelia Zeidler; Karl Welte; David A Weinstein Journal: Curr Opin Hematol Date: 2019-01 Impact factor: 3.284